Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cloudflare Inc (NET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cloudflare Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Cloudflare Inc trades at $268 (market cap $95.42B). The key difference: Cloudflare Inc is far larger — about 21.3× ACADIA Pharmaceuticals Inc.'s market cap, and Cloudflare Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | NET | |
|---|---|---|
Market Cap | $4.49B | $95.42B |
Sector | Health | Technology |
52-Week High | $28.06 | $272.66 |
52-Week Low | $20.06 | $160.16 |
Enterprise Value | $3.69B | $94.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NET trades at $268.77, up 11% today after Scotiabank upgraded the stock citing AI growth potential. The stock shows strong bullish momentum with a consensus analyst rating of 'Buy' (70% of 40 analysts) and a price target of $246.58. Recent earnings beats and revenue growth to $2.17B in 2025 highlight operational strength, though negative net margins and high valuations (P/S 37.22) pose challenges. Technical indicators signal bullish trends with resistance near $262.
Outlook: Growth driven by AI infrastructure demand and strategic partnerships offers upside, but high valuation and lack of profitability increase risk. Investors should weigh robust revenue growth against margin pressures and competitive threats in the cloud sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
